BEIJING (Reuters) – China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. Oligomannate, which uses extract from marine brown algae as raw material, received a conditional… Read More: China gives conditional OK to its first self-developed Alzheimer’s drug »